Alteration in glutathione content and associated enzyme activities in the synaptic terminals but not in the non-synaptic mitochondria from the frontal cortex of Parkinson's disease brains

Neurochemical Research

Volumn 38, Issue 1, 2013, Pages 186-200

  Harish, G ^a   Mahadevan, Anita ^a   Srinivas Bharath, M M ^a   Shankar, S K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Frontal cortex; Glutathione; Mitochondria; Neuropil; Oxidative stress; Parkinson's disease; Synaptosomes

Indexed keywords

GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; SUPEROXIDE DISMUTASE;

ADULT; AGED; AGING; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; MITOCHONDRION; NEUROPIL; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SYNAPSE; SYNAPTOSOME;

ADULT; AGED; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CITRATE (SI)-SYNTHASE; COLORING AGENTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FRONTAL LOBE; GLUTATHIONE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALATE DEHYDROGENASE; MALE; MIDDLE AGED; MITOCHONDRIA; NEUROPIL; NITRATES; OXIDANTS; PARKINSON DISEASE, SECONDARY; PRESYNAPTIC TERMINALS; PROTEIN CARBONYLATION; SUCCINATE DEHYDROGENASE; SUPEROXIDE DISMUTASE; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84871613895     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0907-x     Document Type: Article

References (62)

1. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427-442
2. Adams JD Jr, Chang ML, Klaidman L (2001) Parkinson's disease-redox mechanisms. Curr Med Chem 8(7):809-814
3. Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31(2):119-130. doi: 10.1002/ana.410310202
4. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32(Suppl):S82-S87
5. Sayre LM, Smith MA, Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8(7):721-738
6. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK (2002) Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64(5-6):1037-1048. doi: 10.1016/S0006-2952(02)01174-7
7. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69(3):1326-1329
8. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52(6):1830-1836
9. Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70(1):268-275
10. Good PF, Hsu A, Werner P, Perl DP, Olanow CW (1998) Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57(4):338-342
11. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56(3):978-982
12. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52(2):381-389
13. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93(7):2696-2701
14. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69(3):1196-1203
15. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26(19):5256-5264. doi: 10.1523/JNEUROSCI.0984-06.2006
16. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54(3):823-827
17. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24(2):197-211
18. Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha TC, Srinivas Bharath MM, Shankar SK (2011) Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem Res 36(8):1452-1463. doi: 10.1007/s11064-011-0471-9
19. Mattson MP, Furukawa K (1998) Signaling events regulating the neurodevelopmental triad. Glutamate and secreted forms of beta-amyloid precursor protein as examples. Perspect Dev Neurobiol 5(4):337-352
20. 2+ overload than nonsynaptic mitochondria. J Biol Chem 281(17):11658-11668. doi: 10.1074/jbc.M510303200
21. Naga KK, Sullivan PG, Geddes JW (2007) High cyclophilin D content of synaptic mitochondria results in increased vulnerability to permeability transition. J Neurosci 27(28):7469-7475. doi: 10.1523/jneurosci.0646-07.2007
22. Chandana R, Mythri RB, Mahadevan A, Shankar SK, Srinivas Bharath MM (2009) Biochemical analysis of protein stability in human brain collected at different post-mortem intervals. Indian J Med Res 129(2):189-199
23. Chinta SJ, Kommaddi RP, Turman CM, Strobel HW, Ravindranath V (2005) Constitutive expression and localization of cytochrome P-450 1A1 in rat and human brain: presence of a splice variant form in human brain. J Neurochem 93(3):724-736. doi: 10.1111/j.1471-4159.2005.03061.x
24. Cash AD, Perry G, Ogawa O, Raina AK, Zhu X, Smith MA (2002) Is Alzheimer's disease a mitochondrial disorder? Neurosci Rev J Brin Neurobiol Neurol Psychiatry 8(5):489-496
25. Onyango I, Khan S, Miller B, Swerdlow R, Trimmer P, Bennett P Jr (2006) Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's disease. J Alzheimers Dis 9(2):183-193
26. Reddy PH, Beal MF (2005) Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev 49(3):618-632. doi: 10.1016/j.brainresrev.2005.03.004
27. Forero DA, Casadesus G, Perry G, Arboleda H (2006) Synaptic dysfunction and oxidative stress in Alzheimer's disease: emerging mechanisms. J Cell Mol Med 10(3):796-805
28. Urano S, Asai Y, Makabe S, Matsuo M, Izumiyama N, Ohtsubo K, Endo T (1997) Oxidative injury of synapse and alteration of antioxidative defense systems in rats, and its prevention by vitamin E. Eur J Biochem 245(1):64-70
29. Martinez M, Ferrandiz ML, Diez A, Miquel J (1995) Depletion of cytosolic GSH decreases the ATP levels and viability of synaptosomes from aged mice but not from young mice. Mech Ageing Dev 84(1):77-81
30. Karunakaran S, Saeed U, Ramakrishnan S, Koumar RC, Ravindranath V (2007) Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Res 1185:8-17. doi: 10.1016/j.brainres.2007.09.019
31. Karunakaran S, Saeed U, Mishra M, Valli RK, Joshi SD, Meka DP, Seth P, Ravindranath V (2008) Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J Neurosci 28(47):12500-12509. doi: 10.1523/jneurosci.4511-08.2008
32. Alladi PA, Mahadevan A, Yasha TC, Raju TR, Shankar SK, Muthane U (2009) Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of Parkinson's disease. Neuroscience 159(1):236-245. doi: 10.1016/j.neuroscience.2008.11.051
33. Douglas MS (1983) Rapid, quantitative isolation of mitochondria from rat liver using Ficoll gradients in vertical rotors. Anal Biochem 131(2):453-457. doi: 10.1016/0003-2697(83)90198-7
34. Frasca JM, Parks VR (1965) A routine technique for double-staining ultrathin sections using uranyl and lead salts. J Cell Biol 25:157-161
35. Harish G, Venkateshappa C, Mahadevan A, Pruthi N, Bharath MM, Shankar SK (2012) Mitochondrial function in human brains is affected by pre and postmortem factors. Neuropathol Appl Neurobiol. doi: 10.1111/j.1365-2990.2012.01285.x
36. Harish G, Venkateshappa C, Mahadevan A, Pruthi N, Bharath MM, Shankar SK (2012) Effect of pre and postmortem factors on the distribution and preservation of antioxidant activities in the cytosol and synaptosomes of human brains. Biopreserv Biobank 10(3):253-265. doi: 10.1089/bio.2012.0001
37. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
38. Jagatha B, Mythri RB, Vali S, Bharath MM (2008) Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med 44(5):907-917. doi: 10.1016/j.freeradbiomed.2007. 11.011
39. Bagnyukova TV, Storey KB, Lushchak VI (2003) Induction of oxidative stress in Rana ridibunda during recovery from winter hibernation. J Therm Biol 28:21-28
40. Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27(3):502-522
41. Hissin PJ, Hilf R (1976) A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74(1):214-226
42. Flohe L, Gunzler WA (1984) Assays of glutathione peroxidase. Methods Enzymol 105:114-121
43. Carlberg I, Mannervik B (1985) Glutathione reductase. Methods Enzymol 113:484-490
44. Guthenberg C, Alin P, Mannervik B (1985) Glutathione transferase from rat testis. Methods Enzymol 113:507-510
45. Cohen G, Farooqui R, Kesler N (1997) Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci USA 94(10):4890-4894
46. Srere PA (1969) [1] Citrate synthase: [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)]. In: John ML (ed) Methods in enzymology, Vol 13. Academic Press, Waltham, pp 3-11
47. Pennington RJ (1961) Biochemistry of dystrophic muscle. Mitochondrial succinate-tetrazolium reductase and adenosine triphosphatase. Biochem J 80:649-654
48. Kitto GB, Lewis RG (1967) Purification and properties of tuna supernatant and mitochondrial malate dehydrogenases. Biochimica et Biophysica Acta (BBA)-Enzymol 139(1):1-15. doi: 10.1016/0005-2744(67)90107-6
49. Albers DS, Beal MF (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl 59:133-154
50. Banerjee R, Starkov AA, Beal MF, Thomas B (2009) Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 1792(7):651-663. doi: 10.1016/j.bbadis.2008.11.007
51. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787-795. doi: 10.1038/nature05292
52. Choi SW, Gerencser AA, Lee DW, Rajagopalan S, Nicholls DG, Andersen JK, Brand MD (2011) Intrinsic bioenergetic properties and stress sensitivity of dopaminergic synaptosomes. J Neurosci 31(12):4524-4534. doi: 10.1523/jneurosci.5817-10.2011
53. Ansari MA, Scheff SW (2010) Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 69(2):155-167. doi: 10.1097/NEN.0b013e3181cb5af4
54. Pocernich CB, Cardin AL, Racine CL, Lauderback CM, Butterfield DA (2001) Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int 39(2):141-149
55. Roychowdhury S, Wolf G, Keilhoff G, Horn TF (2003) Cytosolic and mitochondrial glutathione in microglial cells are differentially affected by oxidative/nitrosative stress. Nitric Oxide 8(1):39-47
56. Schnellmann RG, Gilchrist SM, Mandel LJ (1988) Intracellular distribution and depletion of glutathione in rabbit renal proximal tubules. Kidney Int 34(2):229-233
57. Radunovic A, Porto WG, Zeman S, Leigh PN (1997) Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex. Neurosci Lett 239(2-3):105-108
58. Harish G, Venkateshappa C, Mahadevan A, Pruthi N, Bharath MMS, Shankar SK (2011) Effect of storage time, postmortem interval, agonal state, and gender on the postmortem preservation of glial fibrillary acidic protein and oxidatively damaged proteins in human brains. Biopreserv Biobank 9(4):379-387. doi: 10.1089/bio.2011.0033
59. Harish G, Venkateshappa C, Mahadevan A, Pruthi N, Srinivas Bharath MM, Shankar SK (2011) Glutathione metabolism is modulated by postmortem interval, gender difference and agonal state in postmortem human brains. Neurochem Int 59(7):1029-1042. doi: 10.1016/j.neuint.2011.08.024
60. Gomez A, Ferrer I (2010) Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol 120(2):155-167. doi: 10.1007/s00401-010-0669-y
61. Riederer BM (1989) Antigen preservation tests for immunocytochemical detection of cytoskeletal proteins: influence of aldehyde fixatives. J Histochem Cytochem 37(5):675-681
62. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142(2):128-130